Alder BioPharmaceuticals Inc. (NASDAQ:ALDR)’s share price traded down 0.5% on Friday . The company traded as low as $26.07 and last traded at $26.45, with a volume of 170,307 shares traded. The stock had previously closed at $26.58.

A number of equities analysts have weighed in on the stock. Jefferies Group reaffirmed a “buy” rating and set a $61.00 price target on shares of Alder BioPharmaceuticals in a research note on Thursday, June 9th. Zacks Investment Research raised shares of Alder BioPharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, May 30th. Wells Fargo & Co. assumed coverage on shares of Alder BioPharmaceuticals in a research note on Thursday, April 21st. They set an “outperform” rating on the stock. Brean Capital initiated coverage on shares of Alder BioPharmaceuticals in a research note on Wednesday, April 20th. They set a “buy” rating and a $45.00 price target on the stock. Finally, Credit Suisse Group AG reissued an “outperform” rating and issued a $40.00 target price on shares of Alder BioPharmaceuticals in a research note on Tuesday, March 29th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $52.00.

The firm has a 50-day moving average of $27.65 and a 200-day moving average of $25.72. The stock’s market cap is $1.35 billion.

Alder BioPharmaceuticals (NASDAQ:ALDR) last posted its earnings results on Thursday, April 28th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by $0.04. During the same period last year, the company earned ($0.40) EPS. On average, analysts predict that Alder BioPharmaceuticals Inc. will post ($3.25) EPS for the current year.

In other Alder BioPharmaceuticals news, insider John A. Latham sold 6,401 shares of the stock in a transaction dated Friday, May 27th. The shares were sold at an average price of $30.05, for a total transaction of $192,350.05. Following the sale, the insider now owns 248,601 shares of the company’s stock, valued at approximately $7,470,460.05. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Mark James Litton sold 6,000 shares of the stock in a transaction dated Monday, June 13th. The stock was sold at an average price of $28.94, for a total transaction of $173,640.00. Following the sale, the insider now directly owns 74,567 shares in the company, valued at approximately $2,157,968.98. The disclosure for this sale can be found here.

A number of large investors recently modified their holdings of the company. Nationwide Fund Advisors raised its stake in shares of Alder BioPharmaceuticals by 103.6% in the fourth quarter. Nationwide Fund Advisors now owns 30,380 shares of the biopharmaceutical company’s stock worth $1,003,000 after buying an additional 15,457 shares in the last quarter. ProShare Advisors LLC raised its stake in shares of Alder BioPharmaceuticals by 8.6% in the fourth quarter. ProShare Advisors LLC now owns 38,476 shares of the biopharmaceutical company’s stock worth $1,271,000 after buying an additional 3,058 shares in the last quarter. Pyrrho Capital Management LP raised its stake in shares of Alder BioPharmaceuticals by 205.0% in the fourth quarter. Pyrrho Capital Management LP now owns 63,000 shares of the biopharmaceutical company’s stock worth $2,081,000 after buying an additional 42,343 shares in the last quarter. California Public Employees Retirement System raised its stake in shares of Alder BioPharmaceuticals by 834.5% in the fourth quarter. California Public Employees Retirement System now owns 81,300 shares of the biopharmaceutical company’s stock worth $2,685,000 after buying an additional 72,600 shares in the last quarter. Finally, Wells Fargo & Company MN raised its stake in shares of Alder BioPharmaceuticals by 290.6% in the fourth quarter. Wells Fargo & Company MN now owns 269,774 shares of the biopharmaceutical company’s stock worth $8,911,000 after buying an additional 200,707 shares in the last quarter.

Alder Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.